GKOS GLAUKOS Corp
Financings ·
Second-quarter net loss was $19.9 million. SpyGlass says its IPO proceeds and cash will fund operations through 2028 and that it will need substantial additional funding after that.
Defendants are SpyGlass Pharma and employee Long Doan. SpyGlass countersued Glaukos on May 22 over contract interference, and the court moved trial to January 2027.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $507.4 million | $383.5 million |
| Net income (loss) | -$187.7 million | -$146.4 million |
| Cash from operations | -$14.8 million | -$61.3 million |
| Cash and equivalents | $90.8 million | $169.6 million |
GLAUKOS Corp trades under the ticker GKOS on NYSE.
GLAUKOS Corp is listed on NYSE.
Our directory records GLAUKOS Corp under United States.
aibio.space lists GLAUKOS Corp among 2,820 public biotech companies and publishes its news here as stories appear.
$507.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
GLAUKOS Corp reported a net loss of $187.7 million for the fiscal year ended Dec 31, 2025, and used $14.8 million of cash in operations, per its annual report to the SEC.
$162.3 million in cash at Sep 30, 2026, per its 10-Q.
GLAUKOS is named in 2 of our stories about other companies, most recently: "SpyGlass ends June with $234.2 million and says cash lasts through 2028" (Aug 6, 2026); "SpyGlass countersues Glaukos in trade-secret case; trial moved to January 2027" (May 22, 2026). Source.
Press Follow on this page to add GLAUKOS to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming GLAUKOS so far, in Financings, Legal.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio